Method for determining the response to cancer therapy

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7833698
APP PUB NO 20010044124A1
SERIAL NO

09760119

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to a method for determining the response to cancer therapy in an individual using image analysis.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
VENTANA MEDICAL SYSTEMS, INC.TUCSON, AZ188

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bacus, Sarah S Hinsdale, US 26 456

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (1)
* 5972622 Method of detecting apoptosis using an anti-human GP46 monoclonal anti-body 8 1997
 
Cell Analysis Systems, Inc. (1)
* 4741043 Method of and an apparatus for image analyses of biological specimens 125 1985
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2)
* 5665549 Comparative genomic hybridization (CGH) 88 1995
* 6447997 Gene coding for GADD153 as a clinical diagnostic and prognostic in cancer therapy 5 1997
 
3M INNOVATIVE PROPERTIES COMPANY (1)
* 6372895 Fluorogenic compounds 20 2000
 
Celtrix Pharmaceuticals, Inc. (1)
* 5772998 Monoclonal antibodies to transforming growth factor-beta and methods of use 19 1995
 
HEALTH RESEARCH, INC. (1)
* 5498522 Methods for the use of spermidine/spermine N.sup.1 -acetyltransferase as a prognostic indicator and/or a tumor response marker 33 1993
 
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (1)
* 2004/0058,320 Reagents and methods for identifying and modulating expression of tumor senescence genes 1 2001
 
OSI PHARMACEUTICALS, INC. (1)
* 5852035 Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines 22 1997
 
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF COMMERCE (1)
* 5389523 Liposome immunoanalysis by flow injection assay 15 1992
 
CLI ONCOLOGY, INC. (1)
* 5536642 Diagnostic and prognostic methods for solid non-lymphoid tumors and their metastases 7 1993
 
PROMEGA CORPORATION (1)
* 6350452 Apoptosis marker antibodies and methods of use 13 1999
 
UNISYS CORPORATION (1)
* 5935801 Monoclonal antibody that detects apoptotic antigen 7 1996
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
BAYER HEALTHCARE LLC (1)
* 2007/0020,704 Diaryl ureas with kinase inhibiting activity 18 2004
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 16, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 16, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00